<DOC>
	<DOCNO>NCT00495118</DOCNO>
	<brief_summary>The purpose study document long-term safety 25 , 37.5 , 50 mg long-acting injectable risperidone give via injection gluteal muscle every 2 week subject schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>A Long-term Safety Study Long-acting Injectable Risperidone Schizophrenia Schizoaffective Disorder Patients .</brief_title>
	<detailed_description>Noncompliance take medication common among people schizophrenia , frequent cause relapse symptom . A long-acting injectable formulation ensure slow steady release risperidone period several week would eliminate need take medication daily basis , improve compliance . This open-label , international , multicenter study subject schizophrenia schizoaffective disorder complete risperidone microspheres arm study RIS-INT-62 , complete study RIS-INT-85 , drop risperidone microspheres arm study RIS-INT-62 due treatment 75 mg long-acting injectable risperidone . Patients begin study within 7 day final visit RIS-INT-62 RIS-INT-85 study . The end point visit RIS-INT-62 RIS-INT-85 study serf first visit open-label study . Patients start study dose last risperidone microsphere injection receive previous study , dose 12.5 mg low high previously receive dose . Patients receive 75 mg risperidone microsphere injection study RIS-INT-62 continue dose attempt make decrease dose 50 mg within 3 month . The total study duration plan least 1 year approval long-acting injectable risperidone respective country . The study hypothesis treatment long-acting injectable formulation risperidone every 2 week least 1 year safe well tolerate , assessed adverse event reporting , extrapyramidal symptom rating scale , laboratory test , vital sign measurement , physical examination , body weight measurement , electrocardiogram , injection site evaluation . Patients receive injection risperidone depot microspheres ( 25 , 37.5 , 50 , 75 mg ) gluteal muscle 2-weekly interval least 1 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia ( patient RISINT62 RISINT85 ) schizoaffective disorder ( patient RISINT62 ) accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criteria patient complete risperidone microspheres arm RISINT62 , complete RISINT85 , drop risperidone microspheres arm RISINT62 due treatment 75 mg longacting injectable risperidone inform consent sign patient patient otherwise healthy basis prestudy physical examination medical history . A DSMIV Axis I diagnosis schizophrenia schizoaffective disorder pregnant breastfeed woman female patient childbearing potential without adequate contraception history severe drug allergy hypersensitivity subject know unresponsive risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>long-acting injectable</keyword>
</DOC>